Oligonucleotide drugs, as a new class of biomolecular therapeutics, demonstrate significant potential in gene expression regulation through precise targeting of mRNA. However, the complexity of these drugs presents a series of challenges for preclinical bioanalysis, including demands for detection sensitivity, specificity, and stability.
The identification and analysis of impurity structures are crucial steps in ensuring the safety and efficacy of pharmaceuticals. Inadequate impurity research may pose risks to the safety and effectiveness of medications. Therefore, researchers and biopharmaceutical companies must conduct a series of tests to ensure impurities are effectively controlled and managed.
The preclinical bioanalysis of XDC drugs is not only a process of scientific exploration but also a challenge that requires exceptional skill and innovative thinking. Preclinical bioanalysis is a complex, multidimensional, and multi-step process that requires comprehensive evaluation of a drug’s pharmacokinetics, immunogenicity, safety, and efficacy. It requires researchers to possess a high level of expertise and innovation in drug design, sample processing, and analytical method development to ensure the accuracy and reliability of preclinical bioanalysis.
High-Performance Liquid Chromatography (HPLC) purification technology is a crucial purification technique in the biopharmaceutical industry, used to separate various components in a mixture based on their different chemical properties.
Gas Chromatography-Mass Spectrometry (GC-MS) is a commonly used analytical technique that combines the methods of Gas Chromatography (GC) and Mass Spectrometry (MS).
Liposomal drugs, as a major breakthrough in modern medicine, not only significantly enhance drug solubility, stability, and bioavailability but also greatly reduce toxic side effects on healthy tissues.
Gas Chromatography (GC) is an efficient physical separation technique based on the principle of separating different substances in a chromatographic column through the flow of a carrier gas.
In PK studies, special administration methods may increase drug concentration in the target tissue, enhance therapeutic effects, or reduce the incidence of adverse reactions. Yufeng Meng, the Assistant Director of DMPK at Medicilon, provides insights on the techniques and applications of target organ biopsy in PK studies. This information aims to help reduce confusion and challenges in PK trials.
API quality research is not only a technical discussion but also a core issue concerning the safety and efficacy of medications. Medicilon’s Cloud Lecture Hall invites Jianmei Wang from the Process Department to provide a comprehensive and in-depth analysis of API quality research from multiple perspectives. Jianmei will address potential issues in API quality research and explain how to effectively handle them one by one.
On July 8th, it’s the 20th World Allergy Day. Let’s once again focus on this increasingly serious global public health issue. Allergic diseases such as allergic rhinitis, asthma, atopic dermatitis, and conditions like diarrhea caused by peanut allergies not only significantly impact the quality of life for hundreds of millions globally but also impose a heavy economic burden on the global economy.
Address: 1 Broadway, Cambridge, MA02142 (America)
Tel: +1(626)986-9880(U.S. – West Coast)
Address: Allia Future Business Centre Kings Hedges Road
Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954 (Europe)
Email: marketing@medicilon.com
Address: 5th Floor, 24, Seochojungang-ro 8-gril, Seocho-gu, Seoul,
06643 South Korea
Tel: +82 70-8269-5849
Address: No.585 Chuanda Road, Pudong New Area, Shanghai
(Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
